explore -WSS

explore

author：fashion 2025-09-06 02:13:07 - browse：1

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Even great ERs can’t make up for American health disparities

knowledge

WSS

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

China sends large group of warplanes, navy ships towards Taiwan in forceful display

The debate over Covid

Quicker fix for pulse oximeters urged during FDA public meeting

Covid misinformation case heads to Supreme Court

Cybersecurity threat forces Lurie Children's to take systems offline

entertainment

explore

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Medicare proposal to cover medical devices draws a mixed reaction

General Catalyst, Summa Health deal will turn on physician buy

Hollywood unions extend contract negotiations for actors

New Ultima Genomics DNA sequencer can read genome for $100

Wildfire smoke exposes gaps in outdoor worker protections

What we need to know about Arena Bioworks

How one medical school became remarkably diverse

Sickle cell gene therapy cures need to be accessible in Africa

focus

Some dementia cases could be undiagnosed liver disease

Medicare drug price negotiation’s day in court

Biden administration opens offers in Medicare drug price negotiations

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Time to name cancers by genetics, not organ of origin, expert says

Some dementia cases could be undiagnosed liver disease

knowledge

focus

hotspot

Wikipedia